TOPLINE: Nearly 12% of individuals using preexposure prophylaxis (PrEP) for HIV prevention, were diagnosed with alcohol use disorder (AUD) within 6 months of initiating PrEP, whereas nearly 3% were diagnosed before initiation. Fewer than 9% of those diagnosed received any US Food and Drug Administration (FDA)–approved medication for AUD. METHODOLOGY: Researchers carried out a retrospective … Read more
TOPLINE: A recent study found that antiretroviral therapy adherence below 90% was associated with significantly lower odds of viral suppression among women living with HIV. METHODOLOGY: Researchers analyzed data from community-based prospective cohort study including women living with HIV across British Columbia, Ontario, and Quebec between 2013 and 2018. Overall, 1187 participants (median age, 42 … Read more
TOPLINE: Use of nucleoside reverse transcriptase inhibitors (NRTIs), but not other medications for HIV, was associated with a significantly reduced risk for Alzheimer’s disease (AD) in an analysis of two national databases. NRTIs are antiretroviral drugs that block the activation of inflammasome. METHODOLOGY: This study included data of nearly 272,000 US individuals from two national … Read more
TOPLINE: Switching from a boosted protease inhibitor (bPI)–based regimen to bictegravir plus emtricitabine plus tenofovir alafenamide (B/F/TAF) maintained virological suppression over 48 weeks in patients with HIV who had preexisting resistance to nucleoside reverse transcriptase inhibitors (NRTIs), however with increased adverse events. METHODOLOGY: This phase 4 trial assessed the safety and efficacy of switching from … Read more
TOPLINE: Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. METHODOLOGY: Researchers conducted a randomized, noninferiority, phase 4 trial to evaluate the efficacy and safety of dolutegravir plus lamivudine in untreated patients with HIV with no preliminary drug resistance testing. Overall, 223 participants (median … Read more
Cases of gonorrhea and syphilis skyrocketed between 2022 and 2023 in European Union/European Economic Association countries, reported the European Centre for Disease Prevention and Control (ECDC) in its latest Annual Epidemiological Reports on sexually transmitted infections (STIs). Between 2014 and 2023, the ECDC reported a 321% increase in cases of gonorrhea, a 100% increase in … Read more
Every week, 4000 young cisgender women aged 15-24 years contract HIV globally, according to 2023 data. Infections in this age group accounted for 44% of the new global infections that year, highlighting the vulnerability of this population to AIDS. Despite these alarming figures, awareness of and access to preventive measures, such as pre-exposure prophylaxis (PrEP) … Read more